ライフサイエンスコーパス: abiraterone acetate

1 l patients who received at least one dose of abiraterone acetate.

2 ecline in CTCs after starting treatment with abiraterone acetate.

3 this multicenter, two-stage, phase II study, abiraterone acetate 1,000 mg was administered once daily

4 Patients received oral abiraterone acetate (1 g) once daily and prednisone (5 m

5 a 1:1 ratio to receive ADT alone or ADT plus abiraterone acetate (1000 mg daily) and prednisolone (5

6 Participants received oral doses of abiraterone acetate (1000 mg daily) and prednisone (5 mg

7 onse system in a 1:1 ratio to receive either abiraterone acetate (1000 mg once daily) plus prednisone

8 e randomly assigned 1088 patients to receive abiraterone acetate (1000 mg) plus prednisone (5 mg twic

9 Abiraterone acetate, 1000 mg, once daily by mouth with p

10 Abiraterone acetate, 1000 mg, once daily with prednisone

11 rednisone twice daily with either 1000 mg of abiraterone acetate (797 patients) or placebo (398 patie

12 In the past year abiraterone acetate, a CYP17 (17alpha-hydroxylase/17, 20

13 with overexpressed androgen receptor, and by abiraterone acetate, a CYP17A inhibitor that blocks ster

14 Abiraterone acetate (AA) is a potent and selective inhib

15 In the phase III study COU-AA-301, abiraterone acetate (AA) plus prednisone (P) prolonged o

16 not reduce serum androgens as effectively as abiraterone acetate (AA), a prodrug of abiraterone, a CY

17 This is the first evidence that abiraterone acetate achieves sustained suppression of te

18 Journal of Medicine describe the utility of abiraterone acetate, an androgen biosynthesis inhibitor,

19 Abiraterone acetate, an androgen biosynthesis inhibitor,

20 We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthes

21 al was to evaluate the antitumor activity of abiraterone acetate, an oral, specific, irreversible inh

22 A third agent, abiraterone acetate, an orally administered CYP17 inhibi

23 ls of novel hormonal agents, with a focus on abiraterone acetate and enzalutamide (MDV3100).

24 t of novel anti-androgen therapies including abiraterone acetate and enzalutamide.

25 Phase III data with abiraterone acetate and phase II data with MDV-3100, alo

26 te cancer previously treated with docetaxel, abiraterone acetate and prednisone offer significant ben

27 ith clinically significant pain at baseline, abiraterone acetate and prednisone resulted in significa

28 7]; p=0.0056) were significantly better with abiraterone acetate and prednisone than with prednisone

29 -related event was significantly longer with abiraterone acetate and prednisone than with prednisone

30 el CYP17 inhibitors, including ketoconazole, abiraterone acetate, and VN/124-1, which are agents curr

31 Randomized, phase III trials of abiraterone acetate are underway to define the future ro

32 n, development of sustained side-effects, or abiraterone acetate becoming available in the respective

33 for these patients have expanded to include abiraterone acetate, cabazitaxel and enzalutamide.

34 Fasted or fed cohorts received abiraterone acetate doses of 250, 500, 750, or 1,000 mg

35 The development of cabazitaxel, abiraterone acetate, enzalutamide, radium-223, and sipul

36 This phase I dose-escalation study of abiraterone acetate evaluated safety, pharmacokinetics,

37 n this early-access protocol trial to assess abiraterone acetate for patients with metastatic castrat

38 n observed: 354 (65%) of 546 patients in the abiraterone acetate group and 387 (71%) of 542 in the pl

39 Overall, 365 (67%) patients in the abiraterone acetate group and 435 (80%) in the placebo g

40 all survival was significantly longer in the abiraterone acetate group than in the placebo group (34.

41 ac disorders (41 [8%] of 542 patients in the abiraterone acetate group vs 20 [4%] of 540 patients in

42 ce daily) plus prednisone (5 mg twice daily; abiraterone acetate group) or placebo plus prednisone (p

43 Abiraterone acetate has significant antitumor activity i

44 her support the favourable safety profile of abiraterone acetate in patients with chemotherapy-naive

45 01 to enable worldwide preapproval access to abiraterone acetate in patients with metastatic castrati

46 Abiraterone acetate is a prodrug of abiraterone, a selec

47 or men with metastatic CRPC, and approval of abiraterone acetate is anticipated based on the results

48 Abiraterone acetate plus prednisolone improves survival

49 The abiraterone acetate plus prednisone and prednisone-alone

50 iving prednisone alone subsequently received abiraterone acetate plus prednisone as crossover per pro

51 alysis of the trial, assessing the effect of abiraterone acetate plus prednisone on overall survival,

52 Abiraterone acetate plus prednisone significantly improv

53 Abiraterone acetate plus prednisone significantly improv

54 al analysis of the phase 3 COU-AA-301 study, abiraterone acetate plus prednisone significantly prolon

55 the randomised, phase 3 COU-AA-301 trial of abiraterone acetate plus prednisone versus placebo plus

56 he individual-patient level in this trial of abiraterone acetate plus prednisone versus prednisone al

57 randomized, double-blind phase III trial of abiraterone acetate plus prednisone versus prednisone al

58 ng/mL or lower within 12 months of starting abiraterone acetate plus prednisone.

59 Abiraterone acetate potently disrupts intracrine androge

60 8 months, overall survival was longer in the abiraterone acetate-prednisone group than in the placebo

61 alemia, were more frequently reported in the abiraterone acetate-prednisone group than in the placebo

62 , and favorable benefit-harm balance include abiraterone acetate/prednisone, enzalutamide, and radium

63 Abiraterone acetate/prednisone, enzalutamide, or (223)Ra

64 The inhibition of androgen biosynthesis by abiraterone acetate prolonged overall survival among pat

65 llow-up of more than 4 years, treatment with abiraterone acetate prolonged overall survival compared

66 5%) of the 40 received PRO-related labeling (abiraterone acetate, ruxolitinib phosphate, and crizotin

67 d to ascertain the most effective regimen of abiraterone acetate to optimise patients' outcomes.

68 Abiraterone acetate was well tolerated and demonstrated

69 Abiraterone acetate was well tolerated.

70 To determine the efficacy of abiraterone acetate with prednisone in these high-risk p